Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.27 1 Raised 2024 Financial Guidance Ranges for Total Revenue of $970 - $1,020 million , Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595 - $625 million , Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of $4.
00 - $4.20 , Representing YOY Growth of 44%-52% SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc.
(NASDAQ: HALO ) ("Halozyme" or the "Company") today reported its financial and operating results for the third quarter ended September 30, 2024 , and provided an update on its recent corporate activities and outlook. "Our robust third quarter financial results highlight the strong execution and accelerating momentum we have across our business and exceeded expectations with total revenue growth of 34% and adjusted EBITDA growth of 60%. Based on the strong performance year-to-date, we have raised our 2024 guidance ranges and expect the advancement of our ENHANZE pipeline and new nominations from two global licensing agreements to support our future growth trajectory," said Dr.
Helen Torley , president and chief executive officer of Halozyme. "In the quarter, the announcement of two highly anticipated partner approvals in the U.S.
for Roche's TEC.
